Table 1.

Patient demographics

Total (N = 329)
Missing (%)N (%)∗
Patient sex   
Male 223 (67.8) 
Female 106 (32.2) 
IEI subgroup   
CID 163 (49.5) 
PD 127 (38.6) 
PAD 39 (11.9) 
Age at HSCT (y)   
Median (IQR) 18.4 (16.6-22.8) 
Time from clinical diagnosis to HSCT (mo)   
Median (IQR) 1 (0.3) 63.1 (13-189.1) 
Age at clinical diagnosis (y)   
Median (IQR) 3 (0.9) 13 (3.6-17.2) 
BMI at HSCT   
Low BMI (<18) 34 (10.3) 74 (25.1) 
Normal/high BMI (≥18)  221 (74.9) 
Infection immediately prior to HSCT   
No 45 (13.7) 136 (47.9) 
Yes  148 (52.1) 
Bronchiectasis at HSCT   
Absent 5 (1.5) 238 (73.5) 
Present  86 (26.5) 
Colitis or protracted diarrhea at HSCT   
Absent 4 (1.2) 255 (78.5) 
Present  70 (21.5) 
Malignancy prior to HSCT   
No 5 (1.5) 263 (80.9) 
Yes  62 (19.1) 
Remission status at HSCT (if prior malignancy)   
No remission 4 (5.6) 23 (39.7) 
Remission  33 (56.9) 
Not evaluated  2 (3.4) 
GLILD at HSCT   
No 18 (5.5) 268 (86.2) 
Yes  43 (13.8) 
Splenectomy prior to HSCT   
No 14 (4.3) 285 (90.5) 
Yes  30 (9.5) 
Hepatic comorbidity   
No 54 (16.4) 239 (86.9) 
Mild  22 (8) 
Moderate/severe  14 (5.1) 
IEI-associated complications (bronchiectasis, colitis, malignancy, GLILD, hepatic comorbidity, and splenectomy)   
None 56 (17) 90 (33) 
One complication  99 (36.3) 
Two or more complications  84 (30.8) 
HCT-CI (Sorror score)   
7 (2.1) 89 (27.6) 
1-2  128 (39.8) 
3-4  59 (18.3) 
>4  46 (14.3) 
Total (N = 329)
Missing (%)N (%)∗
Patient sex   
Male 223 (67.8) 
Female 106 (32.2) 
IEI subgroup   
CID 163 (49.5) 
PD 127 (38.6) 
PAD 39 (11.9) 
Age at HSCT (y)   
Median (IQR) 18.4 (16.6-22.8) 
Time from clinical diagnosis to HSCT (mo)   
Median (IQR) 1 (0.3) 63.1 (13-189.1) 
Age at clinical diagnosis (y)   
Median (IQR) 3 (0.9) 13 (3.6-17.2) 
BMI at HSCT   
Low BMI (<18) 34 (10.3) 74 (25.1) 
Normal/high BMI (≥18)  221 (74.9) 
Infection immediately prior to HSCT   
No 45 (13.7) 136 (47.9) 
Yes  148 (52.1) 
Bronchiectasis at HSCT   
Absent 5 (1.5) 238 (73.5) 
Present  86 (26.5) 
Colitis or protracted diarrhea at HSCT   
Absent 4 (1.2) 255 (78.5) 
Present  70 (21.5) 
Malignancy prior to HSCT   
No 5 (1.5) 263 (80.9) 
Yes  62 (19.1) 
Remission status at HSCT (if prior malignancy)   
No remission 4 (5.6) 23 (39.7) 
Remission  33 (56.9) 
Not evaluated  2 (3.4) 
GLILD at HSCT   
No 18 (5.5) 268 (86.2) 
Yes  43 (13.8) 
Splenectomy prior to HSCT   
No 14 (4.3) 285 (90.5) 
Yes  30 (9.5) 
Hepatic comorbidity   
No 54 (16.4) 239 (86.9) 
Mild  22 (8) 
Moderate/severe  14 (5.1) 
IEI-associated complications (bronchiectasis, colitis, malignancy, GLILD, hepatic comorbidity, and splenectomy)   
None 56 (17) 90 (33) 
One complication  99 (36.3) 
Two or more complications  84 (30.8) 
HCT-CI (Sorror score)   
7 (2.1) 89 (27.6) 
1-2  128 (39.8) 
3-4  59 (18.3) 
>4  46 (14.3) 

IQR, interquartile ranges.

Percentages in this column are calculated from the nonmissing.

All patients had established diagnosis of IEI prior to development of malignancy.

Close Modal

or Create an Account

Close Modal
Close Modal